Chardan Capital restated their buy rating on shares of Ocugen (NASDAQ:OCGN - Free Report) in a research note published on Thursday,Benzinga reports. They currently have a $6.00 price target on the stock.
A number of other research analysts have also weighed in on OCGN. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Ocugen in a report on Monday, January 13th. Maxim Group assumed coverage on shares of Ocugen in a research note on Tuesday, October 15th. They set a "buy" rating and a $4.00 target price for the company.
Get Our Latest Analysis on Ocugen
Ocugen Stock Performance
Ocugen stock traded up $0.00 during midday trading on Thursday, reaching $0.78. 4,522,355 shares of the company's stock were exchanged, compared to its average volume of 5,126,748. The stock's 50-day simple moving average is $0.84 and its 200 day simple moving average is $1.09. The firm has a market cap of $227.23 million, a price-to-earnings ratio of -4.33 and a beta of 3.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. Ocugen has a 52 week low of $0.50 and a 52 week high of $2.11.
Hedge Funds Weigh In On Ocugen
A number of hedge funds have recently bought and sold shares of OCGN. Xponance Inc. bought a new position in shares of Ocugen in the second quarter worth $25,000. SG Americas Securities LLC acquired a new position in shares of Ocugen in the 3rd quarter valued at approximately $87,000. MetLife Investment Management LLC lifted its holdings in shares of Ocugen by 36.4% during the 3rd quarter. MetLife Investment Management LLC now owns 89,508 shares of the company's stock worth $89,000 after acquiring an additional 23,877 shares during the period. NorthCrest Asset Manangement LLC acquired a new stake in shares of Ocugen during the 3rd quarter worth approximately $90,000. Finally, Intech Investment Management LLC bought a new position in Ocugen in the third quarter valued at approximately $93,000. 10.27% of the stock is owned by institutional investors.
About Ocugen
(
Get Free Report)
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
See Also
Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
